JFR vs OPY

JFR exhibits a stable but fragile financial health profile with a Piotroski F-Score of 4/9 and no Altman Z-Score available. While the fund trades at a discount to book value (P/B 0.87) and below its Graham Number ($8.07), these value metrics are overshadowed by a catastrophic collapse in earnings growth (-52.80% YoY). Most critically, the dividend payout ratio of 300% indicates that the 12.56% yield is unsustainable and likely being funded by return of capital rather than earnings. Combined with a 0/100 technical trend and bearish insider activity, the outlook is negative.

OPY presents a complex profile where deep value metrics conflict with deteriorating forward-looking indicators. The company maintains a stable health profile with a Piotroski F-Score of 6/9 and trades significantly below both its Graham Number ($165.9) and Intrinsic Value ($384.68). However, a critical divergence exists between the trailing P/E (8.78) and the Forward P/E (44.72), suggesting a projected collapse in earnings. Combined with a very bearish technical trend (10/100) and insider selling, the current price reflects a market that is pricing in a significant earnings contraction despite historical growth.